Portage Biotech Inc., of Toronto, said it reached agreement to acquire 100 percent of Salvarx Ltd., of the British Virgin Islands, issuing about 805 million common shares priced at about 8.9 cents per share for an aggregate acquisition cost of $71.7 million. The deal brings Portage interest in 10 products in immuno-oncology.